| scholarly article | Q13442814 |
| P2093 | author name string | Hugh S. Taylor | |
| Valerie A. Flores | |||
| P2860 | cites work | Evolutionary and Biomedical Insights from the Rhesus Macaque Genome | Q22065872 |
| Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B | Q24556548 | ||
| Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes | Q24626206 | ||
| Equine estrogens differentially inhibit DNA fragmentation induced by glutamate in neuronal cells by modulation of regulatory proteins involved in programmed cell death | Q24795759 | ||
| Analysis of the Macaca mulatta transcriptome and the sequence divergence between Macaca and human | Q24812692 | ||
| Molecular characterization of a B-ring unsaturated estrogen: Implications for conjugated equine estrogen components of Premarin | Q27648855 | ||
| Molecular modulation of estrogen-induced apoptosis by synthetic progestins in hormone replacement therapy: an insight into the women's health initiative study | Q28249558 | ||
| Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer | Q28284429 | ||
| Angiogenesis in cancer, vascular, rheumatoid and other disease | Q29547165 | ||
| Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group | Q29615228 | ||
| Estrogen receptors: how do they signal and what are their targets | Q29617958 | ||
| Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. | Q30413295 | ||
| Inhibitory effects of a bazedoxifene/conjugated equine estrogen combination on human breast cancer cells in vitro | Q30456339 | ||
| Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens | Q30456359 | ||
| Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial | Q30456640 | ||
| Use of SERMs for treatment in postmenopausal women | Q30457273 | ||
| Current and evolving approaches to individualizing estrogen receptor-based therapy for menopausal women | Q30457307 | ||
| Proliferative effects of combination estrogen and progesterone replacement therapy on the normal postmenopausal mammary gland in a murine model | Q32067325 | ||
| Linkage of progestin and epidermal growth factor signaling: phosphorylation of progesterone receptors mediates transcriptional hypersensitivity and increased ligand-independent breast cancer cell growth | Q33266857 | ||
| Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study | Q33634928 | ||
| Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination | Q33642558 | ||
| The Molecular Pharmacology of SERMs | Q33730355 | ||
| Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy | Q33898159 | ||
| The EGF receptor: a nexus for trafficking and signaling | Q33911761 | ||
| Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer | Q34110074 | ||
| Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study | Q34115930 | ||
| Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. | Q34177001 | ||
| Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation | Q34191632 | ||
| Breast cancer and hormone-replacement therapy in the Million Women Study | Q34223870 | ||
| Hormone therapy to prevent disease and prolong life in postmenopausal women | Q34262585 | ||
| Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects | Q34317537 | ||
| Progesterone--promoter or inhibitor of breast cancer | Q34323606 | ||
| Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy | Q34325123 | ||
| Effects of different hormone therapies on breast pain in recently postmenopausal women: findings from the Mayo Clinic KEEPS breast pain ancillary study | Q34330784 | ||
| Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study | Q34336219 | ||
| Potency of progestogens used in hormonal therapy: toward understanding differential actions | Q34364806 | ||
| Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. | Q34512916 | ||
| Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study | Q34576753 | ||
| Breast cancer risk in relation to the interval between menopause and starting hormone therapy | Q34577224 | ||
| Reproductive functions of progesterone receptors. | Q34644047 | ||
| Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin | Q34758422 | ||
| Breast cancer after use of estrogen plus progestin in postmenopausal women | Q34938322 | ||
| Progesterone receptors in mammary gland development and tumorigenesis | Q35592113 | ||
| Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells | Q35642132 | ||
| ER beta inhibits proliferation and invasion of breast cancer cells | Q36089436 | ||
| Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial | Q36143058 | ||
| Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. | Q36160032 | ||
| Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis | Q36335555 | ||
| Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial | Q36851595 | ||
| Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis | Q36938367 | ||
| Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women | Q37480990 | ||
| Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials | Q37658616 | ||
| Update in hormone therapy use in menopause | Q37836196 | ||
| Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. | Q37854130 | ||
| Hormone replacement therapy and the risk of breast cancer | Q37909897 | ||
| Using bazedoxifene plus conjugated estrogens for treating postmenopausal women: a comprehensive review | Q37978786 | ||
| Androgens induce divergent proliferative responses in human breast cancer cell lines. | Q38295844 | ||
| Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation | Q38325898 | ||
| Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy | Q38391997 | ||
| Progesterone promotes focal adhesion formation and migration in breast cancer cells through induction of protease-activated receptor-1. | Q39347108 | ||
| Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. | Q39588977 | ||
| Structure activity relationships and differential interactions and functional activity of various equine estrogens mediated via estrogen receptors (ERs) ERalpha and ERbeta | Q39965451 | ||
| p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells | Q40429427 | ||
| Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects | Q40432081 | ||
| Overlapping but distinct gene regulation profiles by glucocorticoids and progestins in human breast cancer cells | Q40728248 | ||
| Antioxidant potential of specific estrogens on lipid peroxidation | Q41522100 | ||
| Raloxifene effects on vasomotor and other climacteric symptoms in postmenopausal women | Q42627380 | ||
| Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). | Q42679385 | ||
| Equine estrogens differentially prevent neuronal cell death induced by glutamate | Q43539177 | ||
| Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and probucol on low-density lipoprotein oxidation in postmenopausal women | Q43809241 | ||
| The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety | Q44927297 | ||
| A limiting factor mediates the differential activation of promoters by the human progesterone receptor isoforms | Q45352912 | ||
| Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. | Q45918585 | ||
| Breast cancer risk in postmenopausal women using estradiol-progestogen therapy | Q46185602 | ||
| Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. | Q46628538 | ||
| Transcriptional profiles of progestogen effects in the postmenopausal breast | Q46651011 | ||
| Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics | Q46945199 | ||
| Antiandrogenic actions of medroxyprogesterone acetate on epithelial cells within normal human breast tissues cultured ex vivo. | Q50954577 | ||
| Tissue selective estrogen complexes (TSECs) and the future of menopausal therapy. | Q51530681 | ||
| Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. | Q51795752 | ||
| The EGF receptor: a nexus for trafficking and signaling | Q56059793 | ||
| The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women | Q57752001 | ||
| Progesterone action in normal mouse mammary gland | Q68581361 | ||
| Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial | Q72677675 | ||
| Progesterone, in addition to estrogen, induces cyclin D1 expression in the murine mammary epithelial cell, in vivo | Q73635441 | ||
| Adverse events reported by postmenopausal women in controlled trials with raloxifene | Q77360659 | ||
| Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function | Q78257311 | ||
| Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells | Q80234351 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 587-602 | |
| P577 | publication date | 2015-09-01 | |
| P1433 | published in | Endocrinology and Metabolism Clinics of North America | Q15763298 |
| P1476 | title | The Effect of Menopausal Hormone Therapies on Breast Cancer: Avoiding the Risk | |
| P478 | volume | 44 |
| Q92035657 | Hormone therapy use and breast tissue DNA methylation: analysis of epigenome wide data from the normal breast study | cites work | P2860 |
Search more.